Premium
Adjuvant chemotherapy for osteogenic sarcoma of the extremity with sequential adriamycin and cisplatin
Author(s) -
Pathak Anand B.,
Advani Suresh H.,
Iyer Rajaram S.,
Pai Suresh K.,
Gopal Ramakrishna,
Nadkarni Kanchan S.,
Saikia Tapan K.,
Kurkure Purna A.,
Nair Chandrika N.,
Pai Vasant R.,
Badhwar Rajesh,
Deshpande Raman K.,
Desai Prafulla B.,
Karakousis Constantine P.
Publication year - 1993
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.2930520313
Subject(s) - medicine , chemotherapy , cisplatin , sarcoma , surgery , adjuvant , osteosarcoma , doxorubicin , adjuvant chemotherapy , toxicity , oncology , cancer , pathology , breast cancer
Twenty‐nine patients with high‐grade nonmetastatic osteogenic sarcoma of the extremities were treated with adjuvant chemotherapy following definitive surgery. Chemotherapy consisted of systemic intravenous Adriamycin and cisplatin in a sequential fashion given for six courses. Nineteen out of 29 patients are alive and continuously disease free over a follow‐up period ranging from 9+ to 30+ months. The relapse‐free survival was 72%, and overall survival for the entire group was 69%. Median survival is not reached yet. Six out of 29 patients relapsed, of which 1 patient is alive for 6+ months after relapse. Three patients died of chemotherapy toxicity. The results were superior to historical controls treated with surgery alone. The need for more aggressive treatment approaches is discussed. © 1993 Wiley‐Liss, Inc.